Cassava Sciences, Inc.
SAVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.01 | 0.05 | 0.60 |
| FCF Yield | -4.48% | -5.66% | -15.66% | -54.02% |
| EV / EBITDA | -3.25 | 1.80 | 2.10 | 0.78 |
| Quality | ||||
| ROIC | -14.52% | -51.55% | -19.25% | -20.23% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.58 | 0.11 | 0.48 | 2.22 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -27.37% | 56.36% | 81.51% | -234.86% |
| Safety | ||||
| Net Debt / EBITDA | 10.00 | 8.10 | 5.49 | 6.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -20,741.40 | -753.32 | -53.95 | -33.55 |